325 related articles for article (PubMed ID: 35214092)
1. Application and Utility of Liposomal Neuroprotective Agents and Biomimetic Nanoparticles for the Treatment of Ischemic Stroke.
Fukuta T; Oku N; Kogure K
Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214092
[TBL] [Abstract][Full Text] [Related]
2. [Development of Biomembrane-mimetic Nanoparticles for the Treatment of Ischemic Stroke].
Fukuta T
Yakugaku Zasshi; 2021; 141(9):1071-1078. PubMed ID: 34471008
[TBL] [Abstract][Full Text] [Related]
3. Applications of Liposomal Drug Delivery Systems to Develop Neuroprotective Agents for the Treatment of Ischemic Stroke.
Fukuta T; Ishii T; Asai T; Oku N
Biol Pharm Bull; 2019; 42(3):319-326. PubMed ID: 30828062
[TBL] [Abstract][Full Text] [Related]
4. [Development of DDS Actively to Overcome the Blood-brain Barrier in the Region of Ischemic Stroke].
Fukuta T; Kogure K
Yakugaku Zasshi; 2020; 140(8):1007-1012. PubMed ID: 32741858
[TBL] [Abstract][Full Text] [Related]
5. Treatment of stroke with liposomal neuroprotective agents under cerebral ischemia conditions.
Fukuta T; Ishii T; Asai T; Sato A; Kikuchi T; Shimizu K; Minamino T; Oku N
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):1-7. PubMed ID: 26455340
[TBL] [Abstract][Full Text] [Related]
6. Biomimetic Nanoparticle Drug Delivery Systems to Overcome Biological Barriers for Therapeutic Applications.
Fukuta T; Kogure K
Chem Pharm Bull (Tokyo); 2022; 70(5):334-340. PubMed ID: 35491189
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke.
Fukuta T; Asai T; Yanagida Y; Namba M; Koide H; Shimizu K; Oku N
FASEB J; 2017 May; 31(5):1879-1890. PubMed ID: 28082354
[TBL] [Abstract][Full Text] [Related]
8. Co-administration of liposomal fasudil and tissue plasminogen activator ameliorated ischemic brain damage in occlusion model rats prepared by photochemically induced thrombosis.
Fukuta T; Yanagida Y; Asai T; Oku N
Biochem Biophys Res Commun; 2018 Jan; 495(1):873-877. PubMed ID: 29162447
[TBL] [Abstract][Full Text] [Related]
9. Pinocembrin Protects Blood-Brain Barrier Function and Expands the Therapeutic Time Window for Tissue-Type Plasminogen Activator Treatment in a Rat Thromboembolic Stroke Model.
Ma Y; Li L; Kong L; Zhu Z; Zhang W; Song J; Chang J; Du G
Biomed Res Int; 2018; 2018():8943210. PubMed ID: 29850586
[TBL] [Abstract][Full Text] [Related]
10. Innovations in Liposomal DDS Technology and Its Application for the Treatment of Various Diseases.
Oku N
Biol Pharm Bull; 2017; 40(2):119-127. PubMed ID: 28154249
[TBL] [Abstract][Full Text] [Related]
11. Drug delivery to the ischemic brain.
Thompson BJ; Ronaldson PT
Adv Pharmacol; 2014; 71():165-202. PubMed ID: 25307217
[TBL] [Abstract][Full Text] [Related]
12. Multimodal nanoprobes evaluating physiological pore size of brain vasculatures in ischemic stroke models.
Zheng S; Bai YY; Changyi Y; Gao X; Zhang W; Wang Y; Zhou L; Ju S; Li C
Adv Healthc Mater; 2014 Nov; 3(11):1909-18. PubMed ID: 24898608
[TBL] [Abstract][Full Text] [Related]
13. Amelioration of cerebral ischemia-reperfusion injury based on liposomal drug delivery system with asialo-erythropoietin.
Ishii T; Asai T; Oyama D; Fukuta T; Yasuda N; Shimizu K; Minamino T; Oku N
J Control Release; 2012 May; 160(1):81-7. PubMed ID: 22342472
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances in the Therapeutic and Diagnostic Use of Liposomes and Carbon Nanomaterials in Ischemic Stroke.
Fernandes LF; Bruch GE; Massensini AR; Frézard F
Front Neurosci; 2018; 12():453. PubMed ID: 30026685
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil.
Fukuta T; Asai T; Sato A; Namba M; Yanagida Y; Kikuchi T; Koide H; Shimizu K; Oku N
Int J Pharm; 2016 Jun; 506(1-2):129-37. PubMed ID: 27107903
[TBL] [Abstract][Full Text] [Related]
16. Advanced drug delivery system against ischemic stroke.
Zhang S; Zhou Y; Li R; Chen Z; Fan X
J Control Release; 2022 Apr; 344():173-201. PubMed ID: 35248645
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil membrane fusogenic nanoliposomal leonurine for targeted ischemic stroke therapy via remodeling cerebral niche and restoring blood-brain barrier integrity.
Tang Z; Meng S; Song Z; Yang X; Li X; Guo H; Du M; Chen J; Zhu YZ; Wang X
Mater Today Bio; 2023 Jun; 20():100674. PubMed ID: 37273794
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic benefits of nanoparticles in stroke.
Panagiotou S; Saha S
Front Neurosci; 2015; 9():182. PubMed ID: 26041986
[TBL] [Abstract][Full Text] [Related]
19. Encapsulation of tissue plasminogen activator in pH-sensitive self-assembled antioxidant nanoparticles for ischemic stroke treatment - Synergistic effect of thrombolysis and antioxidant.
Mei T; Kim A; Vong LB; Marushima A; Puentes S; Matsumaru Y; Matsumura A; Nagasaki Y
Biomaterials; 2019 Sep; 215():119209. PubMed ID: 31181394
[TBL] [Abstract][Full Text] [Related]
20. Normobaric hyperoxia slows blood-brain barrier damage and expands the therapeutic time window for tissue-type plasminogen activator treatment in cerebral ischemia.
Liang J; Qi Z; Liu W; Wang P; Shi W; Dong W; Ji X; Luo Y; Liu KJ
Stroke; 2015 May; 46(5):1344-1351. PubMed ID: 25804925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
